Common gamma chain cytokines-driven optimization of chimeric antigen receptor T cells: Mechanistic insights and future directions

作者：Dezhi Zuo, Zi-Hao Chen, Yu-Meng Jin, Ming Sang, Xiao-Dong Sun, Ai Guo, Xiao-Yang Li, Jinxiang Wu, Kangkang Ji, Hai Zhou · 发表于：World Journal of Clinical Oncology · 年份：2026 · DOI：10.5306/wjco.v17.i2.115451 · 被引用次数：2 · 研究领域：CAR-T cell therapy research、Monoclonal and Polyclonal Antibodies Research、Virus-based gene therapy research

Malignant tumors represent a major threat to human life and health, posing persistent challenges in medical research. While chimeric antigen receptor T (CAR-T) cell therapy has demonstrated breakthrough efficacy in hematological malignancies such as leukemia and lymphoma, its application in solid tumors, including hepatocellular carcinoma, lung cancer, and pancreatic cancer, remains constrained by multiple bottlenecks. These limitations encompass the immunosuppressive tumor microenvironment, insufficient in vivo persistence of CAR-T cells, long-term treatment-induced exhaustion, and off-target toxicity. The interleukin (IL)-2 family cytokines, IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21, also known as gamma chain (γc) cytokines, share the γc (CD132)-Janus kinase 1/3-signal transducer and activator of transcription signaling axis. These cytokines precisely regulate the survival, proliferation, and functional differentiation of immune cells, including T cells and natural killer cells. In CAR-T immunotherapy, γc cytokines are applied in four core scenarios: Facilitating efficient in vitro CAR-T cell expansion to meet therapeutic dosing requirements; enhancing in vivo persistence to extend the therapeutic window; reinforcing effector functions to counteract tumor microenvironment-mediated suppression; and enabling precise cytokine release to mitigate toxicity risks. Technological strategies have evolved from early recombinant protein administration (in vitro and in vivo ) to second-...